GLP-1 (Liraglutide) – Product Information
GLP-1 also known as Liraglutide is a naturally occurring peptide that is known to stimulate insulin secretion. Research shows that it may potentially lower blood sugar levels and improve heart, liver, and lung function, making it a popular choice for researchers to combine with MK 677 which has been known to cause increases in blood sugar levels in subjects.
The peptide has also shown promising results in slowing or preventing the effects of Alzheimer’s disease.
GLP-1 has also been found to potentially improve cardiac muscle glucose uptake. In addition, research has shown that it may possess anti-diabetic and anti-obesity effects. Pure Rawz sells Liraglutide, a synthetic derivative of GLP-1, for research purposes only.
The GLP-1 Liraglutide kit includes:
- 10 Peptides: Our kit includes 10 vials of high-quality peptides, allowing for multiple research applications and experiments.
- 10 Syringes: Each kit is equipped with 10 syringes, ensuring precise and accurate measurement.
- 10 Alcohol Pads: Maintain optimal hygiene and prevent contamination with 10 alcohol pads included in the kit.
- 1 x 20ml Bottle of Bac Water: The kit contains a 20ml bottle of bacteriostatic water (bac water) for peptide reconstitution, providing a sterile and safe solution.
- Packaging with Dry Ice: To preserve the integrity and stability of the peptides, the kit is carefully packaged with dry ice, ensuring a cold and controlled environment during transportation.
- Polar Pack Frozen Ice Pack: Alongside the dry ice, our kit includes a polar pack frozen ice pack to maintain the desired temperature throughout the shipping process.
What is Liraglutide (GLP-1 Analog)?
Liraglutide, also known as Victoza and Saxenda, is an agonist of glucagon-like peptide 1 (GLP-1). It has been shown to potentially inhibit beta cell apoptosis and enhance beta cell growth in vitro. Liraglutide has also been shown to potentially slow gastric emptying to encourage weight loss. [R][R]
Liraglutide was developed by substituting arginine for lysine at position 34 in the GLP-1 peptide. It was developed because GLP-1 has a poor pharmacokinetic profile. The peptide has a half-life of only 2 minutes and is rapidly degraded by the actions of natural enzymes. [R][R]
In healthy individuals and those with type 2 diabetes, Liraglutide has exhibited a potential half-life of 13 hours. Research has shown that its absolute bioavailability (the proportion which produces an active effect) is 55%. Gastrointestinal side effects may potentially occur. [R]
Since November 2010, Liraglutide has been an approved treatment for type 2 diabetes. The US Food and Drug Administration (FDA) has also approved it for chronic weight management in obese patients. Pure Rawz does not sell Liraglutide for human consumption. [R][R]
How does Liraglutide Work?
Here are the proposed mechanisms of action for Liraglutide:
In patients with elevated glucose levels, Liraglutide has been shown to potentially bind to and activate the GLP-1 receptor, causing a dose-dependent increase in insulin. At the same time, Liraglutide lowered inappropriately high glucagon secretion in the body. [R]
There is evidence that the activated GLP-1 receptors in the central nervous system may potentially mediate the bodyweight-lowering effects of exogenously administered Liraglutide. Some of these effects may also be mediated by GLP-1 receptors on vagal nerve fibers lying below the diaphragm. [R]
Liraglutide (GLP-1 Analog) Research
Following is a summary of the existing clinical, animal, and cell-based research on Liraglutide. The information given in this section is for educational purposes only. It doesn’t constitute medical advice. PureRawz sells Liraglutide for laboratory research use only.
Liraglutide and Obesity
Multiple clinical trials have shown that Liraglutide offers potential benefits for weight management.
In a double-blind clinical trial involving 3,731 obesity patients, 1x-daily administration of Liraglutide potentially reduced body weight and improved metabolic control. A total of 63.2% of patients lost at least 5% of their body weight, and 33.1% lost more than 10% of their body weight. [R]
In another study, Liraglutide 3.0 mg was prescribed to 115 patients with an average BMI of 34.8. Four months into the study, the median body weight had decreased by 9.2%. Notably, even those patients who didn’t receive the maximal dose experienced significant weight loss. [R]
Lastly, in a phase III trial, the effects of Liraglutide treatment on patients with a BMI between 30 and 40 were noted. Results from this trial established the potential of Liraglutide 3.0 mg as a substantial weight loss compound. They also highlighted its potential as a long-term weight-loss agent. [R]
Liraglutide and Type-2 Diabetes
Type 2 diabetes occurs when pancreatic beta cells fail to respond to high glucose levels. Research has shown that Liraglutide potentially helps people with type-2 diabetes achieve good glycemic control by stimulating increased insulin secretion when the glucose levels get too high. [R]
In a 52-week placebo-controlled trial, type 2 diabetes patients (ages 10 – 17) were randomly assigned to receive either Liraglutide or placebo. Results from the trial show that Liraglutide, at a dose of up to 1.8 mg per day, was potentially effective in improving glycemic control over the course of the study. [R]
In another study, the effects of Liraglutide treatment on patients with T2D were noted. It was found that 0.6 mg once daily Liraglutide administration potentially improved fasting plasma glucose. This effect was significant after the 1st week and persisted through eight weeks of treatment. [R]
Liraglutide and Cardiovascular Outcomes
According to a clinical study, patients with type 2 diabetes and high cardiovascular risk had a potentially lower risk of death after being treated with Liraglutide than members of the placebo group. Additionally, there were potentially fewer hospitalizations for heart failure in the Liraglutide group than in the placebo group. [R]
In a mouse model of human heart failure, treatment with Liraglutide improved cardiac function. It also reduced cardiac hypertrophy, decreased myocardial fibrosis, and reduced attenuation of atrial weight. Liraglutide treatment was also shown to decrease lung congestion. [R]
Liraglutide and Bone Loss
A 2018 animal study showed that Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes. Liraglutide treatment was found to alleviate reductions in femoral bone mineral density. It also alleviated the destruction of bone micro-architecture. [R]
As part of a human study, Liraglutide 1.8 mg or placebo was administered daily for 26 weeks to patients with type 2 diabetes. Results from this clinical study show that treatment with Liraglutide potentially preserved hip bone mineral density (BMD). The placebo group experienced a potential reduction in hip BMD. [R]
Liraglutide and Alcohol Dependence
Data from a preclinical study suggest that Liraglutide could be tested for the potential treatment of alcohol dependence in human subjects. In the study, Liraglutide treatment reduced alcohol consumption by 30 – 40 percent in rats. It also prevented the origination of the alcohol deprivation effect. [R]
A previous study also identified GLP-1 as a possible therapeutic target in the treatment of alcohol use disorder (AUD). Results from this study, which was conducted on humans, show that GLP-1 had a potential preventive effect on alcohol cravings. [R]
Liraglutide and Osteoarthritis
A preclinical study has shown that Liraglutide possesses strong potential in treating osteoarthritis, the most common form of arthritis. Results show that intra-articular administration of Liraglutide alleviated pain-related behavior in an OA mouse model.
Aside from that, Liraglutide exerted anti-catabolic activity by significantly decreasing the activities of a family of enzymes involved in cartilage breakdown in vitro. Overall, findings from the study showed that Liraglutide could constitute a novel candidate for OA treatment. [R]
Liraglutide and Inflammation
According to a human trial, Liraglutide potentially exerts anti-inflammatory action in obese patients with type 2 diabetes. The research chemical was found to potentially inhibit pro-inflammatory pathways, as well as down-regulate the action of various pro-inflammatory factors. [R]
In another study, Liraglutide demonstrated potential potent anti-inflammatory activity in two cell types involved in osteoarthritis. These include potential inhibition of chondrocyte expression of several mediators involved in inflammation and a shift in M1/M2 macrophage phenotype. [R]
Liraglutide and Lipid Profile
In a randomized, placebo-controlled trial, short-term treatment with Liraglutide potentially improved lipid and lipoprotein profiles in obese patients. These effects are suggestive of a lower risk of atherosclerosis and cardiovascular diseases. [R]
In clinical trials, Liraglutide was found to be generally safe. Adverse effects observed in clinical trials include potential gastrointestinal symptoms such as nausea and vomiting, the risk for pancreatitis, and increased heart rate (with unclear clinical significance). [R]
Frequently Asked Questions
Does GLP-1 Reduce Amyloid Beta Accumulation?
Research has shown that GLP-1 is potentially capable of preventing amyloid beta accumulation. This beta-amyloid precursor protein is the primary component of plaques found in Alzheimer’s disease. Unrelated to that, GLP-1 may promote gene transcription, protecting beta cell insulin stores.
Where to Buy Liraglutide (GLP-1 Analog)?
PureRawz is the best place to buy Liraglutide online.
In order to be the best supplier of research peptides, we provide reference materials with every product we sell. All our products come with an independent, third-party-issued Certificate of Analysis for identification, purity, and concentration.
We offer free international shipping on all orders above $100. You can pay for your purchase through various methods, including PayPal and Bitcoin. Click on the ‘Reviews’ tab to check out what existing customers say about our products and great customer service.
Various clinical trials have shown that Liraglutide is potentially capable of lowering blood sugar levels and inducing a reduction in body weight in obese subjects. Due to its blood sugar control and weight management properties, the FDA has approved Liraglutide for treating diabetes (Type 2) and obesity.
PureRawz sells Liraglutide for testing and laboratory experimentation only.